Breaking News
April 19, 2019 - Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
April 19, 2019 - Exercise can improve non-motor symptoms of Parkinson’s disease
April 19, 2019 - KZFPs play a key role in the regulation of human genome
April 19, 2019 - Extracts of ginkgo seeds show antibacterial activity on pathogens that cause skin infections
April 19, 2019 - Exercises and swimming goggles may reduce adverse effects on eye during long spaceflights
April 19, 2019 - Review suggests a reciprocal relationship between obesity and self-control
April 19, 2019 - Study identifies how enterococci bacteria cause antibiotic-resistant bloodstream infections
April 19, 2019 - Triple negative breast cancer develop resistance to chemotherapy by turning on molecular pathway
April 19, 2019 - Researchers identify key clues to brain and pancreas development
April 19, 2019 - Metformin May Cut Risk for Prematurity, Miscarriage in PCOS
April 19, 2019 - Obese mouse mothers trigger heart problems in offspring
April 19, 2019 - Research sheds light on how leukemia cells become resistant to drugs
April 19, 2019 - Health Tip: Stopping Nosebleeds – Drugs.com MedNews
April 19, 2019 - Pediatric endocrinologist gives iconic ‘Mona Lisa’ a second medical opinion
April 19, 2019 - Tapping patients’ wisdom for C-section pain management
April 18, 2019 - Why have autism rates ‘exploded’ in New Jersey?
April 18, 2019 - Microbiome science may help doctors to improve treatment for children with IBS
April 18, 2019 - New gene therapy cures babies with fatal ‘Bubble Boy’ disease
April 18, 2019 - No female mice? Scientists may still approve NIH grant
April 18, 2019 - What needs to be said about mental health in medicine
April 18, 2019 - Hickenlooper Expanded Medicaid, Created State-Run Marketplace To Insure Nearly All Coloradans
April 18, 2019 - Cancer cells grown in tumor-mimicking environment can help predict the effect of experimental drugs
April 18, 2019 - Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
April 18, 2019 - Adhesive gel bonds to eye surface, could repair injuries without surgery
April 18, 2019 - The future of genomics: A podcast featuring Stanford geneticists
April 18, 2019 - As Syphilis Invades Rural America, A Fraying Health Safety Net Is Failing To Stop It
April 18, 2019 - APOE gene impacts sleep depending on gender and severity of Alzheimer’s
April 18, 2019 - PCORI’s newly approved awards focus on cancer pain and opioid use disorders
April 18, 2019 - New tool provides a standard way to measure effects of caring for survivors of TBI
April 18, 2019 - Smartphone use risks eye examination misdiagnosis
April 18, 2019 - How drug-resistant bugs grow in CF patients’ lungs
April 18, 2019 - Gordana Vunjak-Novakovic Elected to American Academy of Arts & Sciences
April 18, 2019 - Podcast: KHN’s ‘What The Health?’ You Have Questions, We Have Answers
April 18, 2019 - Diabetic drug shows potential to be repurposed as heart disease treatment for non-diabetic patients
April 18, 2019 - New estimation method assesses natural variations in sex ratio at birth
April 18, 2019 - UTA scientist receives $1.17 million grant for cancer research
April 18, 2019 - Coagulation factor VIIa prevents bleeds in hemophilia animal models
April 18, 2019 - Researchers identify risk factors for severe infection after knee replacement
April 18, 2019 - Mass drug administration can offer community-level protection against malaria
April 18, 2019 - FDA’s added sugar label could have substantial health and cost-saving benefits
April 18, 2019 - Researchers identify cause of inherited metabolic disorder
April 18, 2019 - Single strip of white paint not sufficient to protect people who ride bikes
April 18, 2019 - Partner status influences link between sexual problems and self-efficacy in breast cancer survivors
April 18, 2019 - Colorectal Neoplasia Risk Up for Hodgkin Lymphoma Survivors
April 18, 2019 - Rigid spine muscular dystrophy – Genetics Home Reference
April 18, 2019 - Simple bile acid blood test could tell risk of stillbirth
April 18, 2019 - Center for Experimental Therapeutics aims to enable all steps of drug development | News Center
April 18, 2019 - Falling for telephone scams could be an early sign of dementia
April 18, 2019 - Researchers annotate key neuronal proteins in lamprey genome
April 18, 2019 - Study uncovers new biomarker for personalized cancer treatments
April 18, 2019 - Scientists enter research collaboration to find a cure for cancer
April 18, 2019 - Study to compare benefits of tai chi and mindfulness meditation on MS symptoms
April 18, 2019 - Gestational diabetes during pregnancy may increase risk of type 1 diabetes in children
April 18, 2019 - Maternal age has no effect on IVF success, conclude researchers
April 18, 2019 - Is a New Remedy for Body Odor on the Horizon?
April 18, 2019 - Orthostatic hypotension – Genetics Home Reference
April 18, 2019 - Healing the heartbreak of stillbirth and newborn death
April 18, 2019 - New study calls healthiness of eggs into question
April 18, 2019 - Conference to highlight advances in human immune monitoring, bioinformatics | News Center
April 18, 2019 - Bacteria use viruses for self-recognition, study reveals
April 18, 2019 - New adhesive patch could help reduce post-heart attack muscle damage
April 18, 2019 - Researchers analyze the effects of dark play in a serious video game
April 18, 2019 - Scientists revive pig brain cells four hours after death
April 18, 2019 - Filial cannibalism and offspring abandonment may be forms of parental care
April 18, 2019 - Two proteins act in concert to maintain a healthy heart in mice, shows study
April 18, 2019 - Scientists create a functioning 3D printed heart
April 18, 2019 - Non-invasive vagus nerve stimulation improves disease symptoms in patients with rheumatoid arthritis
April 18, 2019 - Majority of men struggle to understand diagnosis and treatment of prostate cancer
April 18, 2019 - Researchers create new small molecules that may combat equine encephalitis viruses
April 18, 2019 - Animal-assisted therapy improves social behavior in patients with brain injuries
April 18, 2019 - Some viruses help protect harmful bacteria in CF patients | News Center
April 18, 2019 - Outpatient healthcare providers inappropriately prescribe antibiotics to 40% of patients
April 18, 2019 - Men who have a resting heart rate of 75 bpm are twice as likely to die early
April 18, 2019 - Novel serum biomarkers to detect NAFLD-related fibrosis
April 18, 2019 - New study delves deeper into individual genomic differences than ever before
April 18, 2019 - Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients
April 18, 2019 - Emotional mirror neurons found in rats
April 18, 2019 - Sylvia Plevritis appointed chair of biomedical data science | News Center
April 18, 2019 - Cervical cancer subtype increasing in several subpopulations of women
April 18, 2019 - Yeast strain provides manufacturing boost to low-calorie sweetener derived from lactose
Cancer cells use tactics to avoid being recognised by immunotherapy agents

Cancer cells use tactics to avoid being recognised by immunotherapy agents

image_pdfDownload PDFimage_print

Researchers have found that bowel cancer cells have a mechanism by which they can switch off some key molecules on their surfaces and thus escape being recognised and killed by the immunotherapy agents.

Image: Colour-enhanced image of human colon cancer cells in culture. Credit: Annie Cavanagh. License: (CC BY 4.0)

Image: Colour-enhanced image of human colon cancer cells in culture. Credit: Annie Cavanagh. License: (CC BY 4.0)

This may provide clues as to why some of the patients do not respond to immunotherapy agents say researchers. Researchers have also suggested methods by which this could be bypassed and effectiveness of immunotherapy could be increased. The results of the study were published this week in the latest issue of the Journal for Immunotherapy of Cancer.

Researchers from the Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust explain that cancer cells can literally “change their spots” so that they are unrecognizable to the immunotherapy agents. They can do this by switching off the key molecules on their surfaces that the immunotherapy agents are trained to recognize.

The team tested samples of bowel cancer cells and found that while some responded well to immunotherapy, others failed to do so. They tested the changes in these tumour cells by examining miniature tumours grown in the labs. The team then tried a combination of available agents to reverse the efficacy of the immunotherapy agents so that they could work for more patients.

The researchers explain that the antibody-based drug cibisatamab – an immunotherapy agent, could work better in more patients if the theory is proved. This study, they add, could also help determine which of the patients would respond well to immunotherapy and which of them would not.

Cibisatamab is one of the new and promising immunotherapy agents that can help identify the cancer cells using immune mechanisms and then kill them selectively. However some patients respond well to this drug while others respond poorly or not at all. Researchers explain that one arm of the drug attaches itself to a molecule present on the surface of the cancer cell. It is called carcinoembryonic antigen (CEA). The other arm of the drug activates a special immune cell called a T cell that can attack and kill the tumour cell. When grown in the labs the team found that some of the tumour cells could hide themselves from treatment by changing their surface molecules and the CEA levels thus reduce.

Cibisatamab has been found to be effective against most bowel cancer patients. This study aimed to look at the cause of its non-efficacy in some of the patients. Biopsy samples were taken from eight bowel cancer patients for this study and mini replicas of the tumours were created in the labs of ICR. Some of the cells contained high numbers of CEA, some low and some were in between, explain the researchers. The team then used cibisatamab to treat these patients and saw that 96 percent of those with high CEA responded well with the drug and only 20 percent with low CEA responded to the drug. They noted that 53 percent of those with mixed levels of CEA responded to the drug.

As a next step the team allowed the cancer cells to grow again in the lab for a month. They noticed that the CEA levels had changed in these regrown tumours. This meant that the cells could change their CEA so as to escape being recognized by the immunotherapy agent. The researchers delved deeper into the genetic make-up of the cells with low CEA on their surfaces and found that these cells have an increase in the WNT pathway of genes. Certain drugs target this pathway in the cancer cells. They realized that if these drugs were combined with cibisatamab, the efficacy of the cibisatamab could be improved in the cancer cells. WNT pathway targeting drugs include tankyrase inhibitors and porcupine inhibitors. They found that when these drugs were used the CEA levels on the cells were increased. This made them vulnerable to the immunotherapy, explained the researchers.

Dr Marco Gerlinger, Team Leader in Translational Oncogenomics at The Institute of Cancer Research, London, and Consultant Oncologist at The Royal Marsden said in a statement, “Cancer is very good at hiding from the body’s immune system. The latest successful immunotherapies work by acting as a matchmaker to bring the immune system together with cancer, so that it can see it and attack it.” He explained, “Our study has found that bowel cancers have a way of dodging even the newest of immunotherapies – changing their spots by altering the levels of a key molecule on the surface of cells, so that they become harder to recognise. We used a new technique for growing miniature replicas of tumours to develop a way of testing whether patients will respond to immunotherapy. And best of all, we were able to identify an existing inhibitor of the WNT pathway which could be used to reverse this process. We hope that this could in future help immunotherapies work in more patients, by making cancer cells more visible to immune cells.” He was the study leader.

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, added, “As we move away from one-size-fits-all therapy for cancer, it’s so important that we are able to identify which patients are most likely to respond to a drug, and do everything we can to avoid resistance to treatment for as long as possible. This research reveals a way in which cancers are able to hide from a promising new type of immunotherapy. Although the work is still in its early stages, it could be used to develop a test for who is most likely to respond to the drug, and points to possible drug combinations that might prevent or delay resistance.”

The study was funded by the Cancer Research UK and the NIHR Biomedical Research Centre at The Institute of Cancer research (ICR) and The Royal Marsden.

Tagged with:

About author

Related Articles